Physician profile
Stephen Wolchok
NPI 1740324102
$1,642.92
in general payments reported to CMS, 2019-2025
13 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.06 · 2020: $28.45 · 2022: $151 · 2023: $443 · 2024: $146 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $360.13 | 2019-2025 | Clareon Panoptix Pro, Hydrus Microstent, Clareon |
| Lumenis Be INC | $321.46 | 2025 | M22 |
| Glaukos Corporation | $296.37 | 2023-2025 | Idosetr |
| Halozyme INC | $191.09 | 2022-2025 | Hylenex Recombinant |
| Johnson & Johnson Surgical Vision, INC. | $146.38 | 2019-2025 | Catalys System, Tecnis Iol |
| Horizon Therapeutics Plc | $106.93 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $57.85 | 2024-2025 | Xdemvy |
| Amgen INC. | $52.50 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $28.71 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $24.09 | 2025 | Miebo |
| Linvatec Corporation | $20.10 | 2024 | Linvatec 2dhd Video Systems |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.47 | 2019 | |
| Omeros Corporation | $17.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wolchok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.